Mode of administration matters: Willingness of people with HIV to switch to future long-acting treatments, and health care professionals' intention to discuss these options.

IF 2.8 3区医学 Q2 INFECTIOUS DISEASES

HIV Medicine Pub Date : 2025-07-02 DOI:10.1111/hiv.70066

Kyra F Mendes de Leon, Kevin Moody, Jeannine F Nellen, Michelle van Vugt, Jan M Prins, Pythia T Nieuwkerk, Marc van der Valk

{"title":"Mode of administration matters: Willingness of people with HIV to switch to future long-acting treatments, and health care professionals' intention to discuss these options.","authors":"Kyra F Mendes de Leon, Kevin Moody, Jeannine F Nellen, Michelle van Vugt, Jan M Prins, Pythia T Nieuwkerk, Marc van der Valk","doi":"10.1111/hiv.70066","DOIUrl":null,"url":null,"abstract":"Introduction: Understanding preferences for long-acting regimens (LAR) of people with HIV and health care professionals (HCPs) is important to optimize and personalize care. We identified preferences for current and future LAR among people with HIV and investigated HCPs' willingness to discuss these options.Methods: This study was conducted during routine clinic visits at Amsterdam UMC between September 2023 and March 2024. Six hypothetical descriptions of LAR represented through vignettes, illustrating administration mode, frequency, location, administrator and side effects, were presented to people with HIV. We asked if people with HIV were willing to consider a switch to each of these vignettes or preferred to continue their current oral regimen. We asked HCPs if they would be likely to discuss each of the vignettes as potential treatment options with people with HIV.Results: Of the 427 people with HIV [median age 56 (46-63) years; 79% males], 89% would be willing to switch to at least one and 10% to all options. The majority, namely, 76%, would consider switching to weekly tablets. Willingness to switch to intramuscular and subcutaneous injections, infusions and implants varied from 33% to 44%. HCPs (n = 23) indicated that they would discuss the different LAR options with 53% to 88% of people with HIV. All LAR options would be discussed in 32% of people with HIV. In 40%-43% of cases when people with HIV would be willing to switch to either intramuscular or intravenous regimes, the HCPs indicated that they would not discuss this treatment option.Conclusions: Most people with HIV would be willing to switch to weekly oral tablets. For the other LAR, lower levels of willingness were observed. Our findings suggest that HCPs may underestimate the willingness to switch to intramuscular injections and intravenous infusions in people with HIV.","PeriodicalId":13176,"journal":{"name":"HIV Medicine","volume":" ","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"HIV Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/hiv.70066","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Understanding preferences for long-acting regimens (LAR) of people with HIV and health care professionals (HCPs) is important to optimize and personalize care. We identified preferences for current and future LAR among people with HIV and investigated HCPs' willingness to discuss these options.

Methods: This study was conducted during routine clinic visits at Amsterdam UMC between September 2023 and March 2024. Six hypothetical descriptions of LAR represented through vignettes, illustrating administration mode, frequency, location, administrator and side effects, were presented to people with HIV. We asked if people with HIV were willing to consider a switch to each of these vignettes or preferred to continue their current oral regimen. We asked HCPs if they would be likely to discuss each of the vignettes as potential treatment options with people with HIV.

Results: Of the 427 people with HIV [median age 56 (46-63) years; 79% males], 89% would be willing to switch to at least one and 10% to all options. The majority, namely, 76%, would consider switching to weekly tablets. Willingness to switch to intramuscular and subcutaneous injections, infusions and implants varied from 33% to 44%. HCPs (n = 23) indicated that they would discuss the different LAR options with 53% to 88% of people with HIV. All LAR options would be discussed in 32% of people with HIV. In 40%-43% of cases when people with HIV would be willing to switch to either intramuscular or intravenous regimes, the HCPs indicated that they would not discuss this treatment option.

Conclusions: Most people with HIV would be willing to switch to weekly oral tablets. For the other LAR, lower levels of willingness were observed. Our findings suggest that HCPs may underestimate the willingness to switch to intramuscular injections and intravenous infusions in people with HIV.

查看原文本刊更多论文

管理模式问题：艾滋病毒感染者是否愿意转向未来的长效治疗，以及卫生保健专业人员是否打算讨论这些选择。

简介：了解艾滋病毒感染者和卫生保健专业人员（HCPs）对长效方案（LAR）的偏好对于优化和个性化护理非常重要。我们确定了HIV感染者对当前和未来的LAR的偏好，并调查了HCPs讨论这些选择的意愿。方法：本研究于2023年9月至2024年3月在阿姆斯特丹UMC进行常规门诊就诊。通过小插图对HIV感染者进行了六种假设的LAR描述，说明了给药方式、频率、地点、管理者和副作用。我们询问艾滋病毒感染者是否愿意考虑切换到这些小插曲或更愿意继续他们目前的口服方案。我们询问医护人员，他们是否有可能与艾滋病毒感染者讨论每个小插曲作为潜在的治疗方案。结果：在427例HIV感染者中[中位年龄56（46-63）岁；（79%男性），89%的人愿意换成至少一种，10%的人愿意换成所有的选择。大多数人（76%）会考虑改用每周一次的平板电脑。愿意改用肌内和皮下注射、输液和植入的比例从33%到44%不等。HCPs （n = 23）表示，他们将与53%至88%的艾滋病毒感染者讨论不同的LAR选择。32%的艾滋病毒感染者将讨论所有LAR方案。在40%-43%的艾滋病毒感染者愿意改用肌肉注射或静脉注射的情况下，卫生保健专业人员表示他们不会讨论这种治疗方案。结论：大多数艾滋病毒感染者愿意每周口服片剂。对于其他LAR，观察到的意愿水平较低。我们的研究结果表明，HCPs可能低估了艾滋病毒感染者转向肌肉注射和静脉输液的意愿。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

HIV Medicine 医学-传染病学

CiteScore

5.10

自引率

10.00%

发文量

167

审稿时长

6-12 weeks

期刊介绍： HIV Medicine aims to provide an alternative outlet for publication of international research papers in the field of HIV Medicine, embracing clinical, pharmocological, epidemiological, ethical, preclinical and in vitro studies. In addition, the journal will commission reviews and other feature articles. It will focus on evidence-based medicine as the mainstay of successful management of HIV and AIDS. The journal is specifically aimed at researchers and clinicians with responsibility for treating HIV seropositive patients.